The Australian Institute of Health and Welfare (AIHW) has just released the latest figures on prostate cancer incidence, mortality, and survival in Australia.
The trends over time are different to the trends we see for many other types of cancer, including a decreasing number of diagnoses since 2009, when cases peaked in Australia. In that year, 22,146 cases were diagnosed, compared to 16,741 cases expected to be diagnosed this year. With an ageing and increasing population, we might ordinarily expect to see the number of men diagnosed increase, but this has not been the case.
What if a simple blood test could predict the effectiveness of a treatment for metastatic castration-resistant prostate cancer (mCRPC)? A recent Australian study suggests this is a possibility. Using a blood test, researchers were able to detect circulating cell free DNA and RNA for altered androgen receptors in the blood of men with mCRPC. Men who had altered androgen receptor DNA or RNA in their blood had a poor response to treatment.
Alarming new research has revealed about 70 per cent of Australians don’t know the signs and symptoms of prostate cancer, prompting Prostate Cancer Foundation of Australia to call for greater public investment in targeted community awareness activities.
The findings have been reported in the Not All Prostate Cancer is the Same report, released by the Prostate Cancer Patient Coalition – Asia Pacific (PCPC).
In a recent study, researchers have found that not all high-grade prostate cancers are the same. The research examined Gleason grade group 5 prostate cancers which are associated with aggressive disease and poor outcome and found that some cancers of this type were more aggressive then others based on differing patterns of gene expression. This is important work that may one day help clinicians decide how best to treat different subgroups of Gleason grade group 5 prostate cancers. The advantage of this is that men with less aggressive cancers may be spared the side effects of intensive treatment while those with more aggressive cancers receive intensive and more targeted treatment.
In one giant leap for advanced prostate cancer, the US Food and Drug Administration (FDA) has this week approved two new PARP inhibitors for the treatment of metastatic castrate resistant prostate cancers which have specific genetic mutations.
Professor Alimonti’s team examined the medical records of 9280 patients (4532 were men) with confirmed COVID-19 infection registered on 1st April 2020. The data were from 68 different hospitals in Veneto, one of the regions hardest hit by the disease in Italy. The information collected about these patients included gender, hospitalisation, admission to intensive care unit, death, tumour diagnosis, prostate cancer diagnosis, and androgen-deprivation therapy (ADT).
The increasing use of PSMA PET scans to image prostate cancer means that metastatic prostate cancer can be detected and targeted more effectively. For a specific type of metastatic disease, known as oligometastatic prostate cancer, emerging evidence suggests that treating the individual oligometastatic sites of disease by metastasis directed therapy (MDT) could delay both the progression of the cancer and the need for androgen deprivation therapy.
In a ground-breaking discovery for men with aggressive prostate cancer, Australian scientists have found a new way to make prostate cancer cells that have spread to bone more visible, so that the immune system can more easily recognise and kill them.
We are in the middle of global pandemic that has escalated very rapidly. The whole world has had to shift its focus to managing this disease. Medical professionals, scientists, biotechnology companies, pharmaceutical companies, government and non-government health bodies are all working together to fight this coronavirus outbreak.
A ground-breaking new Australian trial funded by PCFA has tested the benefits of PSMA-PET scans used at diagnosis. Results show that these scans can replace the current CT and bone scans used by men with high-risk prostate cancer at their time of diagnosis. This week’s research blog asks why this trial is ground-breaking and how it could change clinical practice.
For men with localised prostate cancer, the decision between different treatment and active surveillance options is a very important one. These men want to know their risks of difficult side effects from these options. New research from the US has created a web-based prediction tool for side effects to help men and their doctors in making this decision.
Diagnosis with prostate cancer leads to a wide range of emotions such as fear, anxiety and helplessness. Many men with prostate cancer turn to online groups for help. Online support groups and online communities are a source of information, shared experiences and empowerment for people affected by cancer. A new Australian study has analysed publicly-available conversations from online support groups to track discussions of emotional distress.
Australian professional and volunteer firefighters do a brave and difficult job. Their recent efforts during the 2019-2020 bushfire season have saved many lives. But there is evidence that firefighters have an increased risk of some cancers. Are our firefighters more likely to get prostate cancer?
Difficulty sleeping is a common issue for men with prostate cancer, yet it’s rarely discussed. The symptoms of prostate cancer, side effects of treatments and other issues associated with the disease may be causing sleep problems. This week’s research blog looks at some of the latest research studying sleep for men with prostate cancer.
Men with prostate cancer have stepped up to provide support to their peers in the community, where the healthcare system is lagging behind. Support group leaders are dedicated volunteers with many years’ experience in supporting prostate cancer survivors. A new Australian study has interviewed these experts to hear their priorities for prostate cancer survivorship care.
Hormone therapy is a very effective treatment for prostate cancer, but the side effects are usually difficult to manage. New Australian research has analysed the benefits of exercise for bones and muscles. The trial asked whether starting an exercise program at the same time as starting hormone therapy was better than delaying exercise.
Surgery to remove a prostate tumour can have devastating effects on a man’s ability to have sex. Many men try devices and medications such as Viagra to help them have sex after surgery. This week’s research blog discusses the help available to achieve erections and the latest research comparing erection medications.
Prostate tumours that have spread to the bones cause pain and have a major impact on quality-of-life. They can also lead to serious issues such as spinal compression. New research from the UK has addressed the best way to treat and prevent spinal compression using radiotherapy for men with prostate cancer.
Biopsies are an important step in prostate cancer diagnosis. Improving the accuracy of biopsies could therefore improve the diagnosis process. An exciting new study from The Netherlands has developed an AI (artificial intelligence) to improve the analysis of biopsy tissue and Gleason grading.
Precision medicine for cancer means that the treatment most likely to help the patient is chosen based on test results. This approach is closer to reality for prostate cancer with exciting clinical trial results from 2019. The latest good news comes from a trial linking the benefits of Olaparib (Lynparza) with alterations in DNA repair genes.
Keytruda is an immunotherapy drug that has revolutionised treatment for cancers such as melanoma and lung cancer. Unfortunately, the same level of success has not been seen for prostate cancer. Now a new study has some hopeful results, showing a small proportion of men with late-stage prostate cancer will benefit from Keytruda.
Pelvic floor muscles control the bladder and the flow of urine. Exercising these muscles can help men regain control over urine flow after prostate surgery. New research from Australia has defined an effective pelvic floor exercise program that starts before surgery.
Two anti-hormone drugs are available in Australia to treat metastatic prostate cancer. Both Abiraterone and Enzalutamide can slow the growth of these tumours. A new clinical trial has asked whether men would benefit from taking one after the other, and which order is best.
This November, members of PCFA attended COSA19, the annual meeting of the Clinical Oncology Society of Australia. The COSA meeting brings together clinicians, nurses, allied healthcare and scientists to discuss the clinical management and supportive care for cancer. At this year’s meeting urological cancer was a special theme, meaning there were many prostate cancer presentations. Numerous sessions were dedicated to prostate cancer as well as other important aspects of cancer treatment and care. Some of the highlight sessions were digital health, euthanasia issues and end-of-life care, living with the after-effects of prostate cancer and an opening session dedicated to the future of prostate cancer management.
Tracking prostate cancer cases around the world provides insights into the men most at risk of getting this disease and those who are dying from it. New international data show that the countries with the highest deaths rates from prostate cancer are not necessarily the ones with the highest rates of diagnoses. This week’s blog looks at the patterns of prostate cancer diagnoses around the world and asks how this disease is affecting people living in developing countries.
Every week there is a new story in the media about foods that cause or cure cancer. This week a study from the USA is reported to show that dairy foods are causing prostate cancer. Is it time to throw away the cheese and milk?
Men who are carriers of BRCA2 gene mutations have a higher risk of being diagnosed with prostate cancer. This information provides an opportunity to catch prostate cancer early for these men. The IMPACT trial has tested whether PSA testing at a younger age is useful for men with BRCA gene mutations.